P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1170
Abstract: Upadacitinib (UPA), an oral Janus kinase inhibitor, and ustekinumab (UST), a parenteral IL 12/23 antagonist, are effective treatments for moderately to severely active Crohn’s Disease (CD). In the absence of head-to-head data, a placebo (PBO)-anchored… read more here.
Keywords: moderately severely; upa ust; response; treated pts ... See more keywords